In order to reduce the personal burden of medical expenses and improve the Chinese patients’ sense of acquisition, happiness and security, the Ministry of Human Resources and Social Security (MoHRSS) organized in 2017 the negotiation of the National Medical Insurance Drug List (NMIDL). For the first time, 44 proprietary drugs with definite curative effect, clinical necessity, safety and reliability but with high prices as determined by experts’ review were negotiated for admission into the medical insurance payment standards, of which 36 medicines were successfully admitted into Category B.
The major objectives of this programme are to significantly improve the security of medical insurance medication usage, greatly reduce patients’ personal burden, effectively control the fund expenditure, strongly support the medicine innovation, and achieve win-win results for multi-parties.
In realizing the above-mentioned objectives, the negotiation has achieved great results by applying actuarial technology to analyse the medical insurance big data, evaluating the supporting capacity of medical insurance fund, and scientifically calculating the standard of medical insurance payment. The average price reduction of 36 admitted drugs was 44 per cent, with a maximum reduction of 70 per cent, giving full play to the group purchasing capacity of basic medical insurance.